Guangzhou Hanfang Launches MCT Solutions for Global Pharmaceutical Firms

Domestically Produced Medium Chain Triglycerides Meet International Compliance Standards

【Guangzhou, China】– 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading provider of high-end pharmaceutical lipid excipients, today announces its tailored medium chain triglyceride (MCT) solutions specifically designed for overseas pharmaceutical companies. These domestically developed MCT products break long-standing international monopolies, featuring green extraction technologies and full compliance with global regulatory standards. The solutions are now available globally to address supply chain security challenges for pharmaceutical firms worldwide.

Core Technological Breakthroughs & Product Advantages

Hanfang's MCT products leverage the company's proprietary integrated green technology, combining supercritical CO₂ extraction, membrane separation, and chromatographic separation to replace traditional high-pollution processes. This innovation has achieved a leap in localization rate of high-end pharmaceutical lipid excipients from 10% to 90%, breaking long-term foreign monopolies in the sector. As of 2025, the company holds over 240 patents, providing strong intellectual property protection for its MCT solutions.

Global Compliance & Certifications

To meet global market access requirements, Hanfang's MCT products have obtained multiple international certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. These certifications ensure full compliance with regulatory standards in major markets such as the EU, North America, and Asia-Pacific, enabling seamless integration into overseas pharmaceutical supply chains.

Supply & Customization Services

Hanfang's MCT solutions are now available globally through a multi-channel distribution model including direct sales, authorized agents, custom processing, and technical services. The company serves over 1,000 clients across more than 20 countries and regions, including leading pharmaceutical firms like B. Braun Company and AstraZeneca. Customization options are offered to meet specific formulation requirements of different pharmaceutical products, supporting clients in optimizing their production processes.

Executive Quote

"Our MCT solutions mark a significant step in addressing global pharmaceutical supply chain vulnerabilities," said Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited and leader in pharmaceutical lipid excipient R&D. "By combining domestic technological innovation with international compliance, we aim to provide reliable, cost-effective alternatives for overseas pharmaceutical companies, supporting their sustainable development."

Industry Context & Corporate Strategy

Against the backdrop of growing demand for secure pharmaceutical supply chains, Hanfang's MCT solutions address a critical gap in the global market by offering domestically produced, high-quality excipients. The company's focus on technological innovation aligns with its mission to achieve self-reliance in biomedical technology and safeguard pharmaceutical industry security.

Future Plans

Looking ahead, Guangzhou Hanfang Pharmaceutical Company Limited will continue to invest in R&D of pharmaceutical lipid excipients, expanding its global distribution network and enhancing localized support for overseas clients. The company aims to achieve double-digit growth in revenue and profit in 2026, advancing its vision of becoming a trusted health guardian for families worldwide.

About Guangzhou Hanfang Pharmaceutical Company Limited

Established in 1998, Guangzhou Hanfang Pharmaceutical Company Limited is a core modern pharmaceutical enterprise under the Guangzhou Pharmaceutical Holdings (GPH) Group, specializing in high-end pharmaceutical lipid excipients, APIs, health products, and technical services. It is a national-level specialized and sophisticated "Little Giant" enterprise, home to the only national engineering research center for traditional Chinese medicine (TCM) process technology. With over 334 employees and a global client base spanning more than 20 countries, Hanfang is committed to technological innovation and global compliance to support the biomedical industry.